Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A. 1989;86(23):9193–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 2002;8(4 Suppl):S19-26.

Article  PubMed  Google Scholar 

Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001;8(1):11–31.

Article  CAS  PubMed  Google Scholar 

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.

Article  CAS  PubMed  Google Scholar 

Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12(8):553–63.

Article  CAS  PubMed  Google Scholar 

Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. https://doi.org/10.1016/j.phrs.2013.11.002.

Article  CAS  PubMed  Google Scholar 

Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284(1):99–110.

Article  CAS  PubMed  Google Scholar 

Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–84.

Article  CAS  PubMed  Google Scholar 

Shih AJ, Telesco SE, Radhakrishnan R. Analysis of somatic mutations in cancer: molecular mechanisms of activation in the ErbB family of receptor tyrosine kinases. Cancers. 2011;3(1):1195–231.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Halder S, Basu S, Lall SP, Ganti AK, Batra SK, Seshacharyulu P. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023? Expert Opin Ther Targets. 2023;27:305–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. J Pathol. 2012;227(2):234–44.

Article  CAS  PubMed  Google Scholar 

Zhou Q, Li G, Deng XY, He XB, Chen LJ, Wu C, et al. Activated human hydroxy-carboxylic acid receptor-3 signals to MAP kinase cascades via the PLC-dependent PKC and MMP-mediated EGFR pathways. Br J Pharmacol. 2012;166(6):1756–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013;24(4):438–49.

Article  CAS  PubMed  Google Scholar 

Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 2009;100(1):134–44.

Article  CAS  PubMed  Google Scholar 

Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118(2):257–62.

Article  CAS  PubMed  Google Scholar 

Hynes NE, Schlange T. Targeting ADAMS and ERBBs in lung cancer. Cancer Cell. 2006;10(1):7–11.

Article  CAS  PubMed  Google Scholar 

Sharma SV, Settleman J. ErbBs in lung cancer. Exp Cell Res. 2009;315(4):557–71.

Article  CAS  PubMed  Google Scholar 

Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31–53.

Article  CAS  PubMed  Google Scholar 

Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature. 1981;290(5803):261–4.

Article  CAS  PubMed  Google Scholar 

King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229(4717):974–6.

Article  CAS  PubMed  Google Scholar 

Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11(3):117–27.

Article  CAS  PubMed  Google Scholar 

Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006;16(12):649–56.

Article  CAS  PubMed  Google Scholar 

Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5(3):199–207.

Article  CAS  PubMed  Google Scholar 

Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224–37.

Article  CAS  PubMed  Google Scholar 

Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997–2003.

Article  PubMed  Google Scholar 

Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10(1):25–38.

Article  PubMed  Google Scholar 

Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015;112(45):E6205–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

AACR Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818–31.

Article  Google Scholar 

Yu DH, Tang L, Dong H, Dong Z, Zhang L, Fu J, et al. Oncogenic HER2 fusions in gastric cancer. J Transl Med. 2015;11(13):116.

Article  Google Scholar 

Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002;62(11):3151–8.

CAS  PubMed  Google Scholar 

Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005;102(10):3788–93.

Article  CAS